BRIEF-AzurRx provides update on MS1819 phase II trial
April 11, 2017 at 08:13 AM EDT
* AzurRx Biopharma Inc - Early results indicate that MS1819 exhibits a favorable safety profile Source text for Eikon: Further company coverage:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|